For Healthcare Professionals residing outside the UK and the USA
Univadis Independent Coverage Podcast Report Video Access additional resources

Highlights from ERS 2019

brought to you by
BI

Independent coverage by Univadis®

ERS 2019 - Prevention and management of respiratory infections in primary care.

Community-acquired pneumonia, economic aspects on vaccinations for respiratory disease, and the importance of phenotyping in COPD infections were covered in this session.

Three important issues can be highlighted:

Clinical aspects of community acquired pneumonia, have been reviewed, focusing on microorganisms frequently implicated, differential diagnoses and management. Once pneumonia has been diagnosed, largely based on clinical symptoms and chest x-ray, the severity has to be assessed. When the severity is high, the patient should be referred to a hospital. In a case of low severity (CRB65=0), antibiotic treatment has to be initiated early, preferably with betalactam and avoiding fluorquinolone or dual antibiotic therapy. The treatment has to be maintained 5 days, only considering prolonging this treatment in cases where no improvement is seen.  It is also recommended that steroids are not used, except where the patient has a concomitant condition (eg. COPD, asthma).

In the case of vaccines, the strategies employed between different countries for respiratory disease prevention has been stressed. Its cost-effectiveness has been demonstrated and this should be taken into account when designing vaccination programs. In the case of influenza vaccine, the cost-effectiveness of the high-dose versus standard-dose in terms of hospitalisations due to underlying cardio-respiratory disease has been demonstrated, even in low- and middle-income countries. The influenza vaccine for COPD patients is often well established, although new influenza and pneumococcal vaccines and strategies can be optimised.

References :

van Aalst RRusso EMNeupane N et al. Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease. Vaccine. 2019 Jul 26;37(32):4499-4503.

Marc Miravitlles, Juan Jose Soler-Cataluna, Myriam Calle et al. Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary DiseaseGuía española de la EPOC (GesEPOC) 2017. Arch Bronconeumol.2017:53(6)324-335